Prophylactic immunization against enterotoxin-forming Escherichia coli strains as cause of travellers' diarrhea: Does it make sense and for whom?;Impfprophylaxe gegen ETEC-reisediarrhoe und cholera: Ist sie sinnvoll und für wen?

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 30, 2006, Pages 1660-1664

  Weinke, T ^a   Liebold, I ^a   Burchard, G D ^b   Fruhwein N ^c   Grobusch, M P ^d   Hatz, C ^e   Kollaritsch, H ^f   Nothdurft, H D ^g   Reisinger, E ^h   Rieke, B ⁱ   Schonfeld Ch ^j   Steffenn, R ^k   Stich, A ^l  

^a KLINIKUM ERNST VON BERGMANN   (Germany)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c Bayerische Gesellschaft für Immun und Tropenmedizin   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF ROSTOCK   (Germany)

ⁱ Centrum für Reisemedizin CRM   (Germany)

^j Tropeninstitut Berlin ^*  (Germany)

^k UNIVERSITY OF ZURICH   (Switzerland)

^l Chirurgische Abteilung   (Germany)

more..

Author keywords

Cholera; Traveller's diarhea

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CHOLERA VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ENTEROTOXIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL STRAIN; CHOLERA; DEHYDRATION; ELECTROLYTE DISTURBANCE; ELECTROLYTE INTAKE; ESCHERICHIA COLI; HUMAN; HYPOTENSION; IMMUNIZATION; MUSCLE CRAMP; REVIEW; TACHYCARDIA; TRAVELLER DIARRHEA; BIOSYNTHESIS; DIARRHEA; ENTEROBACTER INFECTION; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; STANDARD; TRAVEL; UTILIZATION REVIEW; VIBRIO CHOLERAE;

CHOLERA; DIARRHEA; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; IMMUNIZATION; TRAVEL; VIBRIO CHOLERAE;

EID: 33747188942     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947813     Document Type: Review

References (31)

1. Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect Dis 2005; 5: 349-360
2. Albert MJ, Siddique AK, Islam MS et al. Large outbreak of clinical cholera due to Vibrio cholerae non-01 in Bangladesh. Lancet 1993; 341: 704
3. Clemens JD, Sack DA, Harris JR et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988; 158: 372-377
4. Clemens JD, Sack DA, Harris JR et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; II: 124-127
5. DuPont HL, Jiang ZD, Okhuysen PC et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Int Med 2005; 142: 805-812
6. DuPont HL. Diarrhoeal disease: current concepts and future challenges. Antimicrobial therapy and prophylaxis. Trans Roy Soc Trop Med Hyg 1993; 87: 31-34
7. Ericsson CD. Travellers' diarrhoea. Int J Antimicrob Agents 2003; 21: 116-124
8. Hakanen A, Jousimies-Somer H, Siitonen H, Huovinen P, Kotilainen P. Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination. Emerg Infect Dis 2003; 9: 267-270
9. Herwaidt BL, de Arroyave KR, Roberts JM, Juranek DD. A multiyear prospective study of the risk factors for and incidence of diarrheal illness in a cohort of Peace Corps volunteers in Guatemala. Ann Int Med 2000; 132: 982-988
10. Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341-345
11. Holmgren J, Bergquist C. New and improved vaccines against cholera. 3rd ed (Hrsg). New York: Marcel Decker, In MM Levine et al. (ed): New Generation Vaccines. 2004: 499-518
12. Jiang ZD, Okhuysen PC, Guo DC et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003; 188: 506-511
13. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Reviews 1998; 11: 142-201
14. Neal KR, Scott HM, Slack RC, Logon RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996; 17: 414-415
15. Peltola H, Siitonen A, Kyrönseppä H et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338: 1285-1289
16. Rendi-Wagner P. Kolloritsch H. Drug prophylaxis for travelers' diarrhea. Clin Inf Uis 2002; 34: 628-633
17. Robert Koch-Institut. Reiseassoziierte infektionsbedingte Erkrankungen im Jahr 2004. Epid Bull 2005; 35: 317-324
18. Robins GW, Wellington K. Rifaximin: A review of its use in the management of traveller's diarrhoea. Drugs 2005; 65: 1697-1713
19. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363: 223-233
20. Scerpella EG, Sanchez JL. III. Mathewson JJ et al. Safety, immunogenicity. and protective efficacy of the whole-cell/recombinant B subunit (WC/rBS) oral cholera vaccine against travelers' diarrhea. J Travel Med 1995; 2: 22-27
21. Sixma TK, Kalk KH. van Zanten BA et al. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J Mol Biol 1993; 230: 890-918
22. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004; 5: 569-573
23. Steinsland H, Valentiner-Branth P, Gjessing HK, Aaby P, Molbak K, Sommerfelt H. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet 2003; 362: 286-291
24. Steffen R, Castelli F, Nothdurft HD, Rombo L, Zuckerman JN. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med 2005; 12: 102-107
25. Steffen R, Acar J, Walker E, Zuckerman J. Cholera: assessing the risk to travellers and identifying methods of protection. Trav Med Inf Dis 2003; 1: 80-88
26. Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. J Travel Med 2001(Suppl) 28: S34-39
27. Steffen R, Collard F, Tornieporth N et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA 1999; 281: 811-817
28. Svennerholm AML, Savarino SJ. Oral inactivated whole cell B subunit combination vaccine against enterotoxigenic Escherichia coli. 3rd ed (Hrsg). New York: Marcel Dekker, In MM Levine et al. (ed.): New generation vaccines. 2004: 737-750
29. Taylor DN, Connor BA, Shlim DR. Chronic diarrhea in the returned traveler. Med Clin North Am 1999; 83: 1033-1052
30. Vila J, Vargas M, Ruiz J, Corachan M, JimenezDeAnta MT, Gascon J. Quinolone resistance in enterotoxigenic Escherichia coli causing diarrhea in travelers to India in comparison with other geographical areas. Antimicrob Agents Chemother 2000; 44: 1731-1733
31. Von Sonnenburg F, Tornieporrh N, Waiyaki P et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 2000; 356: 133-134